

# Gauri G Rao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6560974/publications.pdf>

Version: 2024-02-01

52  
papers

1,017  
citations

471509

17  
h-index

477307

29  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1290  
citing authors

#	ARTICLE	IF	CITATIONS
1	Insights and lessons learned from a prospective clinical pharmacology study in allogeneic hematopoietic stem cell transplant during the COVID-19 pandemic. <i>Clinical and Translational Science</i> , 2022, 15, 583-587.	3.1	2
2	Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant <i>Klebsiella pneumoniae</i> by a bacteriophage-polymyxin combination. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 485-495.	4.1	12
3	Unique mechanistic insights into pathways associated with the synergistic activity of polymyxin B and caspofungin against multidrug-resistant <i>Klebsiella pneumoniae</i> . <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1077-1087.	4.1	10
4	Clinical challenges treating <i>Stenotrophomonas maltophilia</i> infections: an update. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac040.	2.1	39
5	Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study. <i>Journal of Visualized Experiments</i> , 2022, , .	0.3	2
6	Pharmacodynamic and immunomodulatory effects of polymyxin B in combination with fosfomycin against KPC-2-producing <i>Klebsiella pneumoniae</i> . <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106566.	2.5	4
7	Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against <i>Acinetobacter baumannii</i> : A Metabolomic Study. <i>Pharmaceutics</i> , 2022, 14, 786.	4.5	11
8	Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2022, 49, 397-400.	1.8	3
9	A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 89-99.	2.5	21
10	The Complex Roadmap to Infectious Disease Innovation: The Intersection of Bugs, Drugs, and Special Populations. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 793-796.	4.7	2
11	Evaluation Strategies for Triple-Drug Combinations against Carbapenemase-Producing <i>Klebsiella pneumoniae</i> in an <i>In Vitro</i> Hollow-Fiber Infection Model. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1074-1080.	4.7	10
12	Reapproaching Old Treatments: Considerations for PK/PD Studies on Phage Therapy for Bacterial Respiratory Infections. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1443-1456.	4.7	7
13	Moving From Point-Based Analysis to Systems-Based Modeling: Integration of Knowledge to Address Antimicrobial Resistance Against MDR Bacteria. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1196-1206.	4.7	13
14	Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106328.	2.5	11
15	Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106368.	2.5	17
16	Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 577263.	3.5	6
17	Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia. <i>Vaccine</i> , 2021, 39, 6700-6711.	3.8	6
18	Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1525-1537.	2.5	15

#	ARTICLE	IF	CITATIONS
19	A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105833.	2.5	81
20	Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> infections (a meta-analysis dataset). <i>Data in Brief</i> , 2020, 28, 104907.	1.0	2
21	Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 83-92.	2.0	59
22	Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106199.	2.5	8
23	Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 3574-3578.	3.3	37
24	Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Frontiers in Pharmacology</i> , 2019, 10, 1146.	3.5	17
25	Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16
26	Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 418-426.	2.0	2
27	Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 1042-1053.	1.4	11
28	Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans. <i>Pharmaceutical Research</i> , 2018, 35, 26.	3.5	6
29	Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	15
30	Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriaceae mediastinitis. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 51-54.	0.6	1
31	Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for) Tj ETQq1 1 0.784314 rgBT /Overlock 10 62, .	3.2	18
32	Comparison of the composition and in vitro activity of polymyxin B products. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 365-371.	2.5	5
33	Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	67
34	Mechanism-Based Disease Progression Model Describing Host-Pathogen Interactions During the Pathogenesis of <i>Acinetobacter baumannii</i> Pneumonia. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 507-516.	2.5	16
35	<i>In Vitro</i> Assessment of Combined Polymyxin B and Minocycline Therapy against <i>Klebsiella pneumoniae</i> Carbapenemase (KPC)-Producing <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	12
36	Critical Need for Clarity in Polymyxin B Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	15

#	ARTICLE	IF	CITATIONS
37	Polymyxin B in combination with meropenem against carbapenemase-producing <i>Klebsiella pneumoniae</i> : pharmacodynamics and morphological changes. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 224-232.	2.5	46
38	The development and validation of a simple liquid chromatography-tandem mass spectrometry method for polymyxin B1 and B2 quantification in different matrices. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1065-1066, 112-118.	2.3	13
39	Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
40	Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact. <i>Clinical and Translational Science</i> , 2017, 10, 443-454.	3.1	55
41	Multi-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B. <i>PLoS ONE</i> , 2017, 12, e0171834.	2.5	5
42	Triple combination antibiotic therapy for carbapenemase-producing <i>Klebsiella pneumoniae</i> : a systematic review. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2017, 16, 76.	3.8	30
43	Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2870-2880.	3.2	18
44	Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3913-3920.	3.2	43
45	Polymyxin B in combination with doripenem against heteroresistant <i>Acinetobacter baumannii</i> : pharmacodynamics of new dosing strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3148-3156.	3.0	36
46	Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant <i>Acinetobacter baumannii</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 331-336.	2.5	28
47	Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing <i>Klebsiella pneumoniae</i> bacteraemia in a kidney and pancreas transplant patient. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 225-227.	2.5	22
48	Relative Bioavailability of Orally Administered Fosphenytoin Sodium Injection Compared with Phenytoin Sodium Injection in Healthy Volunteers. <i>Pharmacotherapy</i> , 2015, 35, 482-488.	2.6	5
49	Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design. <i>PLoS ONE</i> , 2015, 10, e0138069.	2.5	8
50	Colistin and doripenem combinations against <i>Pseudomonas aeruginosa</i> : profiling the time course of synergistic killing and prevention of resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1434-1442.	3.0	60
51	New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1381-1388.	3.2	30
52	Pharmacodynamic Variability beyond That Explained by MICs. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1730-1735.	3.2	12